comparemela.com

Latest Breaking News On - Oncology global product strategy - Page 1 : comparemela.com

Momelotinib Approved in Europe for Myelofibrosis With Anemia

Momelotinib gets market authorization from the European Commission for patients with MPNs and disease-related splenomegaly or moderate to severe anemia.

Nina mojasEuropean commissionEuropean unionOncology global product strategyMyelofibrosis symptom assessment formTotal symptom scoreHase 3 momentum trial nct04173494Phase 3 simplify 1 trial nct01969838

Superdry looks at saving costs; Ferrexpo loses case

Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions. The economic calendar for this week has the US Federal.

United statesHong kongCity ofUnited kingdomA hong kongSophie roseNina mojasLinda chanJustin le patourelColin godfreyEuropean commissionAlliance news ltdSupreme courtHigh courtAlliance newsBt group

Momelotinib Approaches EU Approval for Myelofibrosis With Anemia

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion supporting the approval of momelotinib for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anemia with primary myelofibrosis, post–polycythemia vera myelofibrosis, or post–essential thrombocytopenia myelofibrosis who have not been exposed to a JAK inhibitor or who had received prior ruxolitinib.

Nina mojasDynamic international prognostic scoring systemEuropean unionEuropean medicines agencyMedicinal productsHuman useMyelofibrosis symptom assessment formOncology global product strategyMomentum trialSimplify 1 trial

Could GSK myelofibrosis treatment gain EU-first approval?

Could GSK myelofibrosis treatment gain EU-first approval?
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Nina mojasCommittee for medicinal products human useEuropean medicines agencyMedicinal productsHuman useSenior vice presidentOncology global product strategy

Australian-developed blood cancer treatment approved by FDA

The FDA has approved GSK's cancer drug Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis in adults with anaemia.

Nina mojasNemes laszloAndrew wilksSenior vice presidentOncology global product strategyProfessor andrewSierra oncologyOne marrow blood cancer

vimarsana © 2020. All Rights Reserved.